Template:Relative affinities of anabolic steroids and related steroids
Jump to navigation
Jump to search
| Steroid | Chemical name | Relative binding affinities (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| PR | AR | ER | GR | MR | SHBG | CBG | ||
| Androstanolone | DHT | 1.4–1.5 | 60–120 | <0.1 | <0.1–0.3 | 0.15 | 100 | 0.8 |
| Boldenone | Δ1-T | <1 | 50–75 | ? | <1 | ? | ? | ? |
| Danazol | 2,3-Isoxazol-17α-Ety-T | 9 | 8 | ? | <0.1a | ? | 8 | 10 |
| Dienolone | ∆9-19-NT | 17 | 134 | <0.1 | 1.6 | 0.3 | ? | ? |
| Dimethyldienolone | ∆9-7α,17α-DiMe-19-NT | 198 | 122 | 0.1 | 6.1 | 1.7 | ? | ? |
| Dimethyltrienolone | ∆9,11-7α,17α-DiMe-19-NT | 306 | 180 | 0.1 | 22 | 52 | ? | ? |
| Drostanolone | 2α-Me-DHT | ? | ? | ? | ? | ? | 39 | ? |
| Ethisterone | 17α-Ety-T | 35 | 0.1 | <1.0 | <1.0 | <1.0 | 25–92 | 0.3 |
| Ethylestrenol | 3-DeO-17α-Et-19-NT | ? | ? | ? | ? | ? | <1 | ? |
| Fluoxymesterone | 9α-F-11β-OH-17α-Me-T | ? | ? | ? | ? | ? | ≤3 | ? |
| Gestrinone | ∆9,11-17α-Ety-18-Me-19-NT | 75–76 | 83–85 | <0.1–10 | 77 | 3.2 | ? | ? |
| Levonorgestrel | 17α-Ety-18-Me-19-NT | 170 | 84–87 | <0.1 | 14 | 0.6–0.9 | 14–50 | <0.1 |
| Mestanolone | 17α-Me-DHT | 5–10 | 100–125 | ? | <1 | ? | 84 | ? |
| Mesterolone | 1α-Me-DHT | ? | ? | ? | ? | ? | 82–440 | ? |
| Metandienone | ∆1-17α-Me-T | ? | ? | ? | ? | ? | 2 | ? |
| Metenolone | ∆1-1-Me-DHT | ? | ? | ? | ? | ? | 3 | ? |
| Methandriol | 17α-Me-A5 | ? | ? | ? | ? | ? | 40 | ? |
| Methasterone | 2α,17α-DiMe-DHT | ? | ? | ? | ? | ? | 58 | ? |
| Methyldienolone | ∆9-17α-Me-19-NT | 71 | 64 | <0.1 | 6 | 0.4 | ? | ? |
| Methyltestosterone | 17α-Me-T | 3 | 45–125 | <0.1 | 1–5 | ? | 5–64 | <0.1 |
| Methyl-1-testosterone | ∆1-17α-Me-DHT | ? | ? | ? | ? | ? | 69 | ? |
| Metribolone | ∆9,11-17α-Me-19-NT | 208–210 | 199–210 | <0.1 | 10–26 | 18 | 0.2–0.8 | ≤0.4 |
| Mibolerone | 7α,17α-DiMe-19-NT | 214 | 108 | <0.1 | 1.4 | 2.1 | 6 | ? |
| Nandrolone | 19-NT | 20 | 154–155 | <0.1 | 0.5 | 1.6 | 1–16 | 0.1 |
| Norethandrolone | 17α-Et-19-NT | ? | ? | ? | ? | ? | 3 | ? |
| Norethisterone | 17α-Ety-19-NT | 155–156 | 43–45 | <0.1 | 2.7–2.8 | 0.2 | 5–21 | 0.3 |
| Norgestrienone | ∆9,11-17α-Ety-19-NT | 63–65 | 70 | <0.1 | 11 | 1.8 | ? | ? |
| Normethandrone | 17α-Me-19-NT | 100 | 146 | <0.1 | 1.5 | 0.6 | 7 | ? |
| Oxandrolone | 2-Oxa-17α-Me-DHT | ? | ? | ? | ? | ? | <1 | ? |
| Oxymetholone | 2-OHMeEne-17α-Me-DHT | ? | ? | ? | ? | ? | ≤3 | ? |
| RU-2309 (17α-Me-THG) | ∆9,11-17α,18-DiMe-19-NT | 230 | 143 | <0.1 | 155 | 36 | ? | ? |
| Stanozolol | 2,3-Pyrazol-17α-Me-DHT | ? | ? | ? | ? | ? | 1–36 | ? |
| Testosterone | T | 1.0–1.2 | 100 | <0.1 | 0.17 | 0.9 | 19–82 | 3–8 |
| 1-Testosterone | ∆1-DHT | ? | ? | ? | ? | ? | 98 | ? |
| Tibolone | 7α-Me-17α-Ety-19-N-5(10)-T | 12 | 12 | 1 | ? | ? | ? | ? |
| Δ4-Tibolone | 7α-Me-17α-Ety-19-NT | 180 | 70 | 1 | <1 | 2 | 1–8 | <1 |
| Trenbolone | ∆9,11-19-NT | 74–75 | 190–197 | <0.1 | 2.9 | 1.33 | ? | ? |
| Trestolone | 7α-Me-19-NT | 50–75 | 100–125 | ? | <1 | ? | 12 | ? |
| Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PR, testosterone for the AR, estradiol for the ER, dexamethasone for the GR, aldosterone for the MR, dihydrotestosterone for SHBG, and cortisol for CBG. Footnotes: a = 1-hour incubation time (4 hours is standard for this assay; may affect affinity value). Sources: [1][2][3][4][5][6][7][8][9][10] | ||||||||
Template documentationSee also
- Anabolic steroid § Comparison of AAS
- Template:Relative affinities of estrogens for steroid hormone receptors and blood proteins
- Template:Affinities of estrogen receptor ligands for the ERα and ERβ
- Template:Pharmacodynamics of progestogens
References
- ^ Delettré J, Mornon JP, Lepicard G, Ojasoo T, Raynaud JP (January 1980). "Steroid flexibility and receptor specificity". J. Steroid Biochem. 13 (1): 45–59. doi:10.1016/0022-4731(80)90112-0. PMID 7382482.
- ^ Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors". J. Steroid Biochem. 27 (1–3): 255–69. doi:10.1016/0022-4731(87)90317-7. PMID 3695484.
- ^ Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, Labrie F, Mornon JP (January 1980). "Steroid hormone receptors and pharmacology". J. Steroid Biochem. 12: 143–57. doi:10.1016/0022-4731(80)90264-2. PMID 7421203.
- ^ Ojasoo T, Raynaud JP (November 1978). "Unique steroid congeners for receptor studies". Cancer Res. 38 (11 Pt 2): 4186–98. PMID 359134.
- ^ Ojasoo T, Raynaud JP, Doé JC (January 1994). "Affiliations among steroid receptors as revealed by multivariate analysis of steroid binding data". J. Steroid Biochem. Mol. Biol. 48 (1): 31–46. doi:10.1016/0960-0760(94)90248-8. PMID 8136304.
- ^ Saartok T, Dahlberg E, Gustafsson JA (June 1984). "Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin". Endocrinology. 114 (6): 2100–6. doi:10.1210/endo-114-6-2100. PMID 6539197.
- ^ Raynaud JP, Ojasoo T, Pottier J, Salmon J (1982). "Chemical substitution of steroid hormones: Effect on receptor binding and pharmacokinetics". In Gerald Litwack (ed.). Biochemical Actions of Hormones. Vol. 9. Academic Press. pp. 305–342. ISBN 9780323153447.
- ^ Cunningham GR, Tindall DJ, Lobl TJ, Campbell JA, Means AR (September 1981). "Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP)". Steroids. 38 (3): 243–62. doi:10.1016/0039-128X(81)90061-1. PMID 7197818.
- ^ Pugeat MM, Dunn JF, Nisula BC (July 1981). "Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma". J. Clin. Endocrinol. Metab. 53 (1): 69–75. doi:10.1210/jcem-53-1-69. PMID 7195405.
- ^ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.